Interview David Segarra – CEO and Co-Founder of aptaTargets

by GENESIS Biomed

David Segarra: “ApToll is an immune modulator to treat ischaemic stroke in the acute phase. We have successfully completed Phase 2a and will soon conduct Phase 2b. We are also testing ApToll for oth...

Read more

Progress in the maturity of the start-ups: the clinical phases

by GENESIS Biomed

The start-ups Oxolife, Peptomyc and aptaTargets, with which GENESIS Biomed collaborates, are advancing in their maturity with the initiation and development of clinical phases and are approaching an e...

Read more

A solid science and the right patent, keys to raise private funding

by GENESIS Biomed

Having a solid scientific project and the right patent to protect it are key to raise funding in health innovation projects, according to the three entrepreneurs that participated in the 3rd webinar o...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream